Mutations associated with imatinib response in CML - Katerina Polakova
Update: 2016-07-30
Description
Dr Katerina Machova Polakova talks to ecancertv at EHA 2016 about single nucleotide polymorphisms (SNPs) associated with response to first line treatment with imatinib for patients with chronic myeloid leukaemia (CML).
She describes mutations in SLC regions that may represent genetic markers for CML, and the benefit to patients and caregivers alike in a fully informed choice of treatment, depending on probable response.
She describes mutations in SLC regions that may represent genetic markers for CML, and the benefit to patients and caregivers alike in a fully informed choice of treatment, depending on probable response.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
